All News

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.

Cambridge University wants rights to the intellectual property generated by its staff. The idea has divided scientists in a university well known for its high-tech spin-outs.

A Swiss team has developed a reliable blood test for younger, live cows. Now it is looking for investment to develop a test for Creutzfeldt-Jakob disease in humans.

On inventive Californians, technology transfer, how to approach the business press, and other insights into R&D management.

"Anything that won't sell, I don't want to invent. Its sale is proof of utility, and utility is success." Thomas A. Edison (1847-1931).

A new Munich-based company that says its patented technologies can reduce household water consumption by 90 per cent on average is looking for more investment.

The UK's National Collection of Yeast Cultures is looking for partners to help it to delve into research on using yeast to contribute to cutting edge science such as fingerprint DNA identification or drug delivery systems

A British pharmaceutical distributor, Beckpharma Ltd., said it licensed two Cuban healthcare products to sell in Europe as part of a broader effort for trade links.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

A new proposal from the European Investment Fund seeks to accelerate the success of European technology transfer projects. A noble idea, says Mary Lisbeth D'Amico in her fortnightly column, but no one has yet stepped up to foot the bill.

OrthoMimetics, the first technology spin-out from the Cambridge-MIT Institute, Cambridge, UK, has begun its search for initial funding.